Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Eton Pharmaceuticals Earnings Call: Key Takeaways

Eton Pharmaceuticals delivered a massive Q3 2026 beat, driven by Hemangiol's full-quarter contribution and record patient counts across all branded products, significantly accelerating their long-term revenue and margin targets.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue up 158% to $57.9M; Hemangiol relaunch was primary driver.
Mgmt ConfidenceExtremely high; claiming to be years ahead of aspirational long-term goals.
Demand VisibilityRecord high active patient counts across all key branded products.
Margin TrendsAdjusted gross margin 80%; adjusted EBITDA margin expanded to 49%.
Op. LeverageSignificant; 50% EBITDA margin achieved despite $3M licensing expense.
Pricing PowerHemangiol net price $8,000-$10,000; ASN-001 expected to have favorable Medicaid rebates.
Vol vs PriceGrowth driven by both volume (patient counts) and favorable product mix.
Segment GrowthStrong performance across Ingrilux, Alkindi, Candidi, Desmoda, Galzin, and Carglumic assets.
New ClientsLicensed Libervant from Aquestive; licensed ET-900 patents from Baylor College.
Capex & Debt$55.6M cash; $5M debt prepayment reduced principal balance to $22M.
RegulatoryLibervant PDUFA late March 2027; Candidi target action date May 2027.
CommentaryManagement emphasizes building a leading rare disease company through aggressive late-stage licensing.
New LaunchesLibervant launch April 2027; ASN-001 launch 2028; Anglidia launch 2027.

Growth

Revenue grew 158% year-over-year to $57.9 million; adjusted EBITDA margin reached 49%.

Outlook

Raised 2026 revenue guidance to >$175M; targeting $500M revenue well ahead of 2030.

Risks

ET-700 proof-of-concept study showed slower-than-ideal release, requiring additional clinical arms in 2027.

Source

The company's earnings call, NASDAQ: ETON, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Eton Pharmaceuticals, Inc.: key numbers

Share price
$63.88Close, Nov 16
Market cap
$1.84B
Shares outstanding
28.84MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Eton Pharmaceuticals, Inc.

All →
4:46 PM ET Form 4
Insider Selling

Eton Pharmaceuticals Chief Commercial Officer Ipek Erdogan-Trinkaus Sells $236K of Stock

Ipek Erdogan-Trinkaus, Chief Commercial Officer, sold 3,500 shares of Eton Pharmaceuticals, Inc. at $67.18 to $67.88 a share (average $67.41) in 2 transactions, worth $236K in total on Nov 10, 2026. Shares held after the trade: 4,081 (-22.1%).

Value
$236K
Shares
3,500
Average price
$67.41
Role
Chief Commercial Officer
Holding change
-22.1%
Trade date
Nov 10, 2026
6:22 PM ET Form 4
Insider Selling

Eton Pharmaceuticals Insider Charles J. Casamento Sells $5.35M of Stock

Charles J. Casamento sold 80,555 shares of Eton Pharmaceuticals, Inc. at $64.33 to $67.87 a share (average $66.35) in 5 transactions, worth $5.35M in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).

Value
$5.35M
Shares
80,555
Average price
$66.35
Holding change
-100.0%
Trade date
Nov 10, 2026
4:36 PM ET 10-Q
Financial Results ▶ Call

Eton Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $35.2M

Eton Pharmaceuticals reported a significant increase in net revenues to $57.9 million for the third quarter of 2026, driven by strong product sales. The company achieved a net income of $35.2 million for the quarter, aided by a $12.9 million income tax benefit related to the reversal of a deferred tax asset valuation allowance.

Key figure
Net income $35.2M
4:17 PM ET 8-K
Financial Results

Eton Pharmaceuticals Financial Results

Eton Pharmaceuticals reported record Q3 2026 revenue of $57.9 million, representing 158% year-over-year growth and surpassing its $200 million annualized revenue run rate goal ahead of schedule. The company achieved a 49% Adjusted EBITDA margin and raised its full-year 2026 revenue guidance to over $175 million.

Term
Q3 2026

“Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. The team also demonstrated exceptional operational execution, significantly expanding margins, and delivering an adjusted EBITDA margin of 49%.”

Sean Brynjelsen, CEO of Eton Pharmaceuticals

“We have also made transformational improvements to our pipeline in recent months with ASN-001 for infantile hemangiomas, and ET-900, our new program evaluating mecasermin in infantile and epileptic spasms.”

Sean Brynjelsen, CEO of Eton Pharmaceuticals
4:03 PM ET 8-K
Clinical Trial Data

Eton Pharmaceuticals Clinical Trial Data

Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.

“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”

Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals
7:00 AM ET 8-K
Research Collaboration

Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine

Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.

Counterparty
Baylor College of Medicine

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.